2024
Blood pressure changes during ketamine infusion for the treatment of depression
Ansari M, Pittman B, Tylee D, Ostroff R, Wilkinson S, Nikayin S. Blood pressure changes during ketamine infusion for the treatment of depression. General Hospital Psychiatry 2024, 90: 62-67. PMID: 38991311, DOI: 10.1016/j.genhosppsych.2024.07.001.Peer-Reviewed Original ResearchKetamine infusionBlood pressure changesBlood pressureRetrospective chart review of patientsChart review of patientsMedical history of hypertensionRetrospective chart reviewHistory of hypertensionSignificant blood pressureDiastolic blood pressureTreatment of depressionSevere hypertensionPatient demographicsHypertensive patientsInfusion sessionsMedical historyHypertensive eventsInfusionPatientsKetamineBP surgeCardiovascular monitoringBloodHypertensionPressure changes
2023
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol
Kitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyMajor depressionSuicidal ideationRelapse preventionBehavioral therapyStudy protocolHigh riskClinical trial study protocolLong-term treatment approachKey secondary outcomesTrial study protocolHigh relapse rateHigh-risk populationSignificant suicidal ideationHospital dischargeSecondary outcomesPrimary outcomeRelapse rateFeasibility trialEsketamineTreatment approachesPatientsSuicide attemptsTherapySupplemental indicationsEfficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Castro M, Wilkinson S, Al Jurdi R, Petrillo M, Zaki N, Borentain S, Fu D, Turkoz I, Sun L, Brown B, Cabrera P. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. CNS Drugs 2023, 37: 715-723. PMID: 37558912, PMCID: PMC10439056, DOI: 10.1007/s40263-023-01026-3.Peer-Reviewed Original ResearchConceptsEsketamine nasal spraySUSTAIN 1Nasal spraySecond inductionMaintenance treatmentMADRS response ratesTreatment-emergent AEsDepression rating scoresNew safety signalsTreatment-resistant depressionTime of relapseLong-term treatmentLong-term trialsEligible patientsOral antidepressantsRemission rateStable remissionSubgroup analysisChronic illnessSafety signalsInterim analysisDepressive symptomsPatientsResponse rateRemissionKetamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.Peer-Reviewed Original ResearchConceptsTreatment-resistant major depressionPatient-reported qualityElectroconvulsive therapyMajor depressionECT groupKetamine groupTreatment phaseMusculoskeletal adverse effectsSubanesthetic intravenous ketamineWeeks of treatmentInitial treatment phaseIntravenous ketamineSecondary outcomesPrimary outcomeNoninferiority marginTrial groupECT clinicsNoninferiority trialPatientsComparative effectivenessKetamineClinical sitesAdverse effectsDepressionThree timesPredictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray
Turkoz I, Nelson J, Wilkinson S, Borentain S, Macaluso M, Trivedi M, Williamson D, Sheehan J, Salvadore G, Singh J, Daly E. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry Research 2023, 323: 115165. PMID: 37019044, DOI: 10.1016/j.psychres.2023.115165.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionEsketamine nasal sprayNasal sprayDay 28Day 8Clinical Global Impression-Severity scoreCGI-S scoresCurrent depressive episodePredictors of responsePlacebo nasal sprayIdentification of predictorsOral antidepressantsBaseline patientAcute trialPooled analysisDepressive episodeRemissionPsychiatric characteristicsPatientsSignificant anxietyYounger ageTreatment assignmentPotential predictorsPhase 3PredictorsEffects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study.
Wilkinson S, Sint K, Forester B, Rhee T. Effects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study. The Journal Of Clinical Psychiatry 2023, 84 PMID: 36700843, DOI: 10.4088/jcp.22m14583.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyFunctional outcomeComorbid depressionPrincipal psychiatric diagnosisRandomized clinical trialsECT cohortECT patientsComparable cohortsSafe treatmentClinical trialsMedicare patientsCurrent treatmentFunctional declineLimited efficacyPropensity score methodsPsychiatric disordersSummary scoresPsychiatric diagnosisLarger sample sizeMultivariate analysisPsychological symptomsDementiaPatientsOlder adultsCohort
2018
Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.
Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. The Journal Of Clinical Psychiatry 2018, 79 PMID: 30063304, PMCID: PMC6296748, DOI: 10.4088/jcp.17m11731.Peer-Reviewed Original ResearchConceptsMood disordersClinical treatmentTreatment-resistant mood disordersResearch protocolLong-term adverse effectsRapid-acting antidepressantsLong-term safetyEmergence of symptomsRemission rateKetamine infusionFourth infusionLabel therapyTerm outcomesAuthors' institutionPsychiatric hospitalTotal infusionPatientsCognitive declineKetamineTotal treatmentInfusionAdverse effectsClinical samplesLong-term basisTreatmentThe Successful Use of Electroconvulsive Therapy in a Patient With Cerebral Aneurysms and a Pituitary Lesion
Kitay B, Katz R, Wilkinson S, Ostroff R. The Successful Use of Electroconvulsive Therapy in a Patient With Cerebral Aneurysms and a Pituitary Lesion. Journal Of Ect 2018, 1. DOI: 10.1097/00124509-900000000-99225.Peer-Reviewed Original ResearchIdentifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans
Wilkinson ST, Agbese E, Leslie DL, Rosenheck RA. Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans. Psychiatric Services 2018, 69: 542-548. PMID: 29385954, PMCID: PMC6248332, DOI: 10.1176/appi.ps.201700364.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyMood disordersClinical characteristicsECT useUse of ECTCharacteristics of patientsProportion of patientsComorbid psychiatric disordersMajor depressive disorderNumber of prescriptionsSubstance use disordersOutpatient psychotherapy visitsECT patientsECT utilization rateMarketScan databasePsychotherapy visitsPsychotropic medicationsDepressive disorderPsychiatric disordersService useUse disordersPatientsECT utilizationBipolar disorderCommercial insurance